粤芯半导体IPO申请昨日获深交所受理 创业板第三套上市标准再次被“激活”

Group 1: Company Overview - Guangdong Yuxin Semiconductor Technology Co., Ltd. (Yuxin Semiconductor) has submitted its IPO application to the Shenzhen Stock Exchange on December 19, 2023, under the third set of listing standards for the ChiNext board [1] - Yuxin Semiconductor is the first 12-inch wafer manufacturing enterprise in Guangdong Province to enter mass production, focusing on analog chip manufacturing [2] - The company has maintained a high level of R&D investment, with R&D expenses accounting for a significant portion of its revenue [2] Group 2: Financial and Operational Plans - Yuxin Semiconductor plans to raise 7.5 billion yuan through its IPO, which will be directed towards its main business, including the construction of a 12-inch integrated circuit analog process production line and R&D for specialized technology platforms [3] - The company aims to enhance its production capacity and establish a strong domestic supply-demand connection to support the localization of equipment, materials, design, EDA, and IP fields [3] Group 3: Future Development Strategy - Yuxin Semiconductor intends to strategically optimize its production capacity and strengthen its specialized technology platform capabilities, transitioning from pure analog foundry to a composite technology platform that integrates analog, digital, and optoelectronic features [4] - The company will continue to increase R&D investment in key business areas such as consumer electronics, industrial control, automotive electronics, and artificial intelligence [4] Group 4: Industry Context and Reforms - The ChiNext board serves as a crucial platform for supporting technological innovation, with recent reforms aimed at accommodating high-quality, unprofitable innovative enterprises [5] - The introduction of the third set of listing standards is expected to broaden financing channels for innovative companies, optimize valuation systems, and support the development of strategic emerging industries like semiconductors and biomedicine [6][7]